References:
  1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013 May 23;368(21):2004-13. doi: 10.1056/NEJMra1216063. PMID: 23697515.
  2. Yakushkin VV, Zyuryaev IT, Khaspekova SG, Sirotkina OV, Ruda MY, Mazurov AV. Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome. Platelets. 2011;22(4):243-51. doi: 10.3109/09537104.2010.547959. Epub 2011 Feb 17. PMID: 21329420.
  3. Bansal AB, Sattar Y, Jamil RT. Eptifibatide. 2022 Jan 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31082110.
  4. Aljundi A, Rahhal A, Dabdoob W. Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia. Case Rep Cardiol. 2020 Jun 9;2020:8386709. doi: 10.1155/2020/8386709. PMID: 32566320; PMCID: PMC7303759.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436–443.
  5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436–443.
  6. O’Shea JC, Hafley GE, Greenberg S, et al; ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001;285:2468–2473.
  7. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet. 1997;349:1422–1428.
  8. Refaat, M., Smith, A. J. C., & Edmundowicz, D. (2007). Eptifibatide-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 25(2), 204–206.  doi:10.1007/s11239-007-0166-x
  9. Pothineni NV, Watts TE, Ding Z, Dai Y, Deshmukh AJ. Eptifibatide-Induced Thrombocytopenia–When Inhibitor Turns Killer. Am J Ther. 2016 Jan-Feb;23(1):e298-9. doi: 10.1097/01.mjt.0000438283.01797.1a. PMID: 24368608.
  10. Coons JC, Barcelona RA, Freedy T, Hagerty MF. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother. 2005 Feb;39(2):368-72. doi: 10.1345/aph.1E244. Epub 2005 Jan 11. PMID: 15644467.
  11. Boettcher BT, Olund TJ, Pagel PS. Acute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery Surgery. Anesth Pain Med. 2016 Jun 21;6(4):e37575. doi: 10.5812/aapm.37575. PMID: 27843778; PMCID: PMC5099974.
  12. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):340S-380S. doi: 10.1378/chest.08-0677. Erratum in: Chest. 2011 May;139(5):1261. Dosage error in article text. PMID: 18574270.